Iowa walk-in clinic announced comprehensive treatment services for viral and bacterial infections, offering rapid testing for ...

The expectation is that COVID-19 will eventually settle into a winter seasonal pattern like other coronaviruses, but the past ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

Heat is helpful for certain pathogens, like bacteria and fungi, that thrive in warm, humid conditions. However, during the ...

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Diagnostics' progress on their PCR platform, with key trials in 2025 and commercialization plans by 2026, targeting U.S. and global markets.

Key Points GAAP revenue jumped 413% year over year to $11.8 million in Q2 2025, but fell far short of analyst estimates, with GAAP revenue of $11.8 million missing the consensus of $23.2 million by 49 ...

WALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended June 30, 2025, and provided recent business highlights.

Seasonal shifts are driving unusual surges in respiratory illnesses in 2025, with COVID-19, influenza, and RSV showing new ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled Retrospective Study Evaluating ...

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory ...